Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab

Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder managed with plasma exchange (PLEX) and steroids. Addition of rituximab (RTX) to initial disease treatment has been shown to lower future relapse rates. Information as to whether upfront cyclophosphami...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Med (Lausanne)
Autors principals: Abou-Ismail, Mouhamed Yazan, Arafah, Yasmin, Fu, Pingfu, Cao, Shufen, Schmaier, Alvin H., Nayak, Lalitha
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657267/
https://ncbi.nlm.nih.gov/pubmed/33195351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.588526
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars